Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes: A 6-month observational study. (PubMed, Medicine (Baltimore)) - Sep 16, 2026 - "In patients with type 2 diabetes and asymptomatic hyperuricemia, elevated SUA was associated with increased cardiovascular risk. Empagliflozin significantly reduced SUA and improved fasting plasma glucose, with a potential trend toward favorable cardiovascular outcomes."
Journal • Observational data • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus
|
|
Khoa Dang Dang Tran; Minh Quan Duc Nguyen; Son Kim Tran
|